Public record
Wegovy: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicaid
Medicaid prescriptions for Wegovy by state
State Medicaid programmes paid for 1,993,883 Wegovy prescriptions in 2025, with $2.60B reimbursed before rebates. California reported the most (1,000,304), followed by Pennsylvania (247,331) and North Carolina (203,087); 49 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 1,993,883 | |
| Total reimbursed before rebates, 2025 | $2.60B | |
| States and territories reporting | 49 | with at least one count CMS did not suppress |
| California | 1,000,304 prescriptions | $1.31B reimbursed |
| Pennsylvania | 247,331 prescriptions | $329.5M reimbursed |
| North Carolina | 203,087 prescriptions | $274.1M reimbursed |
| Michigan | 194,841 prescriptions | $251.8M reimbursed |
| Minnesota | 90,988 prescriptions | $118.8M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Wegovy only (brand-name semaglutide), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for Wegovy
Retail pharmacies paid an average of $653.33 per mL for WEGOVY 0.25 MG/0.5 ML PEN as of 2026-11-11, compared with $652.89 twelve months earlier (+0.1%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value | Note |
|---|---|---|
| WEGOVY 0.25 MG/0.5 ML PEN | $653.33 per mL | 12 months earlier $652.89 (+0.1%) |
| WEGOVY 0.5 MG/0.5 ML PEN | $653.30 per mL | 12 months earlier $652.83 (+0.1%) |
| WEGOVY 1 MG/0.5 ML PEN | $653.07 per mL | 12 months earlier $652.58 (+0.1%) |
| WEGOVY 1.5 MG TABLET | $43.53 per unit | no price on file 12 months earlier |
| WEGOVY 1.7 MG/0.75 ML PEN | $435.57 per mL | 12 months earlier $435.12 (+0.1%) |
| WEGOVY 2.4 MG/0.75 ML PEN | $435.57 per mL | 12 months earlier $435.10 (+0.1%) |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Wegovy (brand-name semaglutide) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
Articles on Wegovy
- Does Aetna (CVS Health) Cover Wegovy? Prior Authorization, Formulary Tier, and Appeal Steps
- Wegovy Cost vs. Alternatives: Comparing Every GLP-1 Option in 2026
- Does Humana Cover Wegovy? Prior Authorization, Formulary Tier, and Appeal Steps
- Does Kaiser Permanente Cover Wegovy? Prior Authorization, Formulary Tier, and Appeal Steps
- Wegovy Patient Assistance for Low-Income: Every Program, Step by Step
- Wegovy VA Coverage Pathway: How Veterans Can Access Semaglutide 2.4 mg